Acute-onset multifocal motor neuropathy (AMMN): how we meet the diagnosis

Giuliana Galassi1, Francesca Girolami

  • 1Department of Neurosciences, University of Modena & Reggio Emilia, Modena, Italy. giulianagalassi@aliceposta.it

Insights

Acute-onset multifocal motor neuropathy (MMN) presents with sudden weakness and persistent conduction blocks. Early diagnosis is crucial for appropriate treatment and prognosis, differentiating it from other neuropathies.

Area of Science:

  • Neurology
  • Neuroimmunology

Background:

  • Multifocal motor neuropathy (MMN) typically presents insidiously with motor weakness and conduction blocks.
  • Acute onset is an uncommon presentation of MMN.

Observation:

  • Four patients presented with acute areflexia, pure motor deficits, and multifocal conduction blocks.
  • Three patients had preceding infections, and two showed anti-GM1 IgM antibodies.
  • Symptoms improved or stabilized with intravenous immunoglobulin (IVIg) therapy.

Findings:

  • Persistent multifocal motor conduction blocks were observed on serial electrophysiological studies.
  • Association with preceding infections and anti-GM1 IgM antibodies suggests an immune-mediated process.
  • Intravenous immunoglobulin (IVIg) demonstrated therapeutic efficacy.

Implications:

  • Acute-onset MMN (AMMN) requires differentiation from other acute immune-mediated neuropathies.
  • Accurate diagnosis impacts long-term patient management and prognosis.
  • This study expands the understanding of MMN spectrum, particularly in acute presentations.

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...